THE IMPACT OF POLYCYSTIC OVARY SYNDROME ON REPRODUCTIVE AND METABOLIC HEALTH
Abstract
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by chronic anovulation, hyperandrogenism, and metabolic dysfunction. It represents one of the most common causes of reproductive impairment among women of reproductive age and is closely linked to long-term metabolic disturbances including insulin resistance, obesity, dyslipidemia, and increased cardiovascular risk. Despite the high prevalence of PCOS, diagnostic challenges and variable clinical presentations continue to contribute to delayed detection and suboptimal management. Understanding the relationship between reproductive and metabolic abnormalities is essential for improving clinical outcomes and optimizing individualized treatment strategies.
Full text
Noyabr, 2025-Yil 262 THE IMPACT OF POLYCYSTIC OVARY SYNDROME ON REPRODUCTIVE AND METABOLIC HEALTH ¹Safarova Gulrux ²Bazarova Shaxrizoda ³Mo‘minova Madina ¹²³Clinical Coordinators, Department of Obstetrics and Gynecology, DKTF No. 2, Samarkand State Medical University. https://doi.org/10.5281/zenodo.17699295 Introduction: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by chronic anovulation, hyperandrogenism, and metabolic dysfunction. It represents one of the most common causes of reproductive impairment among women of reproductive age and is closely linked to long-term metabolic disturbances including insulin resistance, obesity, dyslipidemia, and increased cardiovascular risk. Despite the high prevalence of PCOS, diagnostic challenges and variable clinical presentations continue to contribute to delayed detection and suboptimal management. Understanding the relationship between reproductive and metabolic abnormalities is essential for improving clinical outcomes and optimizing individualized treatment strategies. Objective: To analyze the impact of PCOS on reproductive function and metabolic health, identify the most significant clinical manifestations, and evaluate the role of early diagnosis in preventing long-term complications. Materials and Methods: A cross-sectional, descriptive study was conducted among women aged 18–35 diagnosed with PCOS based on the Rotterdam criteria. Clinical data included menstrual patterns, ovulatory status, androgen levels, body mass index, metabolic markers, and ultrasound findings. Laboratory investigations assessed fasting glucose, insulin levels, lipid profile, and hormonal indicators including LH/FSH ratio and free testosterone. Statistical analysis evaluated correlations between reproductive and metabolic parameters to determine patterns of disease severity. Results: The majority of patients demonstrated irregular menstrual cycles and clinical signs of hyperandrogenism including hirsutism and acne. Ultrasound evaluation revealed increased ovarian volume and multiple peripheral follicles consistent with PCOS morphology. Metabolic assessment indicated a high prevalence of insulin resistance, impaired fasting glucose, central obesity, and dyslipidemia. Strong correlations were found between elevated androgen levels, anovulation, and metabolic disturbances. Patients with higher BMI showed more severe menstrual irregularities, greater hormonal imbalance, and significantly higher risk of prediabetes. Discussion: Findings confirm that PCOS affects both reproductive and metabolic systems, with metabolic dysfunction amplifying the severity of reproductive abnormalities. Insulin resistance was identified as a central pathogenic mechanism linking androgen excess, ovulatory dysfunction, and increased cardiovascular risk. These results highlight the importance of comprehensive clinical evaluation that integrates reproductive and metabolic markers to ensure timely diagnosis and targeted therapy.
Noyabr, 2025-Yil 263 Lifestyle modification combined with pharmacological interventions remains the most effective strategy to improve metabolic status and restore ovulatory function. Conclusion: PCOS significantly impairs reproductive and metabolic health, and early recognition of its multifaceted clinical presentation is essential to prevent progressive metabolic complications. Integrated management focusing on hormonal balance, metabolic control, and lifestyle optimization is crucial for improving long-term outcomes and enhancing quality of life in affected women. References: 1. БЕЛКА, F. S. Р. С. Р. (2022). В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. 2. Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от иммунного статуса пациентов. междисциплинарный подход по заболеваниям органов головы и шеи, 103. 3. ЖД, З., and А. БС. "РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И ДДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES 3.3 (2024): 300-307. 4. Zhalalova, D. Z. OCT angiography in the assessment of retinal and choreoretinal microcirculation in patients with uncomplicated arterial hypertension International Ophthalmological Congress IOC Tashkent 2021. 5. Zhalalova, D. Z. Evaluation of markers of endothelial dysfunction in tear fluid in patients with arterial hypertension. Journal of Biomedicine in Amaliet. Tashkent-2022, Volume No., No. WITH. 6. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. 7. Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). Combined dental and eye pathology. Science and innovation, 1(8), 91-100. 8. Zhalalova, D. Z. (2022). Pulatov US MICROCIRCULATORY DISORDERS IN THE VASCULAR SYSTEM OF THE BULBAR CONJUNCTIVA WITH INITIAL MANIFESTATIONS OF INSUFFICIENT BLOOD SUPPLY TO THE BRAIN. European journal of molecular medicine, 2(5). 9. Жалалова, Д. З. (2021). ОКТ-ангиография при оценке сосудистого русла сетчатки и хориоидеи. Биология ва тиббиет муаммолари, 6(130), 211-216. 10. Жалалова, Д. З. (2022). Классификационые критерии изменений сосудов сетчатки при артериальной гипертензии. In Международная научная конференция Университетская наука: взгляд в будущее (pp. 56-64). 11. Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З. (2016). Эффективность комбинированного лечения пациентов с центральной
Noyabr, 2025-Yil 264 серозной хориоретинопатией. Вестник Башкирского государственного медицинского университета, (2), 64-66. 12. Жалалова, Д. З. Оценка маркеров эндотелиальной дисфункции в слезной жидкости у пациентов с артериальной гипертензиейЖурнал «Биомедицина ва амалиет». Тошкент-2022, Том №, №. С. 13. Жалалова, Д. З. (2021). ОКТ-ангиография в оценке ретинальной и хореоретинальной микроциркуляции у пациентов с неосложненой артериальной гипертензией/I Международный офтальмологческий конгресс IOC Uzbekistan, 2021 г. Ташкент, с, 96. 14. Shernazarov, F., Jalalova, D., Azimov, A., & CAUSES, S. A. (2022). SYMPTOMS, APPEARANCE, TREATMENT OF VARICOSE VEINS. 15. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. 16. Shernazarov, F., Tohirova, J., & Jalalova, D. (2022). Types of hemorrhagic diseases, changes in newboens, their early diagnosis. Science and innovation, 1(D5), 16-22. 17. Zhalalova, D. Z. (2022). The content of endothelin and homocysteine in blood and lacrimal fluid in patients with hypertensive retinopathy Web of Scientist: International Scientific Research Journal. ISSUE, 2, 958-963. 18. Shernazarov, F., & Zuhridinovna, J. D. (2022). Microcirculation disorders in the vascular system of the bulbar conjunctiva in the initial manifestations of cerebral blood supply deficiency. Science and innovation, 1(Special Issue 2), 515-522. 19. Zhalalova, D. Z. (2022). Modern aspects of neuroprotektive treatment in hypertensive retinopathy Web of Scientist: International Scientific Research JournalVolume 3. ISSUE, 2, 949-952. 20. Жалалова, Д. З. (2009). Метод комбинированного лечения диабетической ретинопатии. Врач-аспирант, 37(10), 864-868. 21. Жалалова, Д. З. (2023). Результаты оценки эффективности комплексного лечения у пациентов с 3-4 стадиями гипертонической ангиоретинопатии. Miasto Przyszłości, 41, 33-36. 22. ЖД, З., & ИЖ, Ж. (2024). КЛАССИФИКАЦИЯ ГИПЕРТОНИЧЕСКОЙ РЕТИНОПАТИИ НА ОСНОВЕ ДАННЫХ ОПТИЧЕСКОЙ КОГЕРЕНТНОЙ ТОМОГРАФИИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 336-342. 23. ЗЖД, Ж. (2024). КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ПОКАЗАТЕЛИ ОРГАНА ЗРЕНИЯ У ПАЦИЕНТОВ С ИШЕМИЧЕКИМИ ИЗМЕНЕНИЯМИ СОСУДОВ СЕТЧАТКИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 286-293. 24. ЖД, З. (2024). ОЦЕНКА КЛИНИЧЕСКИХ И ФУНКЦИОНАЛЬНЫХ ПОКАЗАТЕЛЕЙ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 330-335. 25. Жалалова, Д. З. (2023). Актуальность проблемы изменений глазного дна при артериальной гипертензии. Miasto Przyszłości, 41, 37-40.